The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs
GM Oderda, GD Lawless, GC Wright… - Personalized …, 2018 - Future Medicine
… Grant D Lawless … Grant D Lawless … 4 Willey VJ, Kopenski F, Lawless GD. Beyond the
myths: finding benefit design solutions that address the true costs of high healthcare use. Am. …
myths: finding benefit design solutions that address the true costs of high healthcare use. Am. …
Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention
BACKGROUND: African‐American women have increased breast cancer mortality
compared with white women. Diagnostic and treatment gaps may contribute to this disparity. …
compared with white women. Diagnostic and treatment gaps may contribute to this disparity. …
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
…, BL Pohlman, VA Morrison, GD Lawless… - … (Williston Park, NY), 2001 - europepmc.org
Records from 653 patients treated between 1991 and 1998 in the Oncology Practice Patterns
Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns …
Study (OPPS) were analyzed to determine contemporary chemotherapy delivery patterns …
[HTML][HTML] The working patient with cancer: implications for payers and employers
GD Lawless - American Health & Drug Benefits, 2009 - ncbi.nlm.nih.gov
… In this article, Dr Lawless shows that working patients with cancer today are more likely to
remain with the same employer for more than 5 years after their initial diagnosis, and that the …
remain with the same employer for more than 5 years after their initial diagnosis, and that the …
Outpatient cancer drug costs: changes, drivers, and the future
RJ Halbert, C Zaher, S Wade, J Malin, GD Lawless… - Cancer, 2002 - Wiley Online Library
BACKGROUND To the authors' knowledge, no analysis has examined the specific components
of drug spending for overall cancer care. The authors' objective was to quantify and …
of drug spending for overall cancer care. The authors' objective was to quantify and …
Cost-effectiveness of autologous bone marrow transplantation
GD Lawless - American journal of health-system pharmacy, 1995 - academic.oup.com
The impact of filgrastim on the use of health care resources during recovery from autologous
bone marrow transplantation (ABMT) was studied. The charts for patients with metastatic …
bone marrow transplantation (ABMT) was studied. The charts for patients with metastatic …
Beyond the myths: finding benefit design solutions that address the true costs of high healthcare use.
VJ Willey, F Kopenski, GD Lawless - The American journal of …, 2008 - europepmc.org
Chronic and severe health problems place an enormous financial burden on individuals,
employers, and health plan providers, requiring all to make tough decisions about healthcare. …
employers, and health plan providers, requiring all to make tough decisions about healthcare. …
Oncology health care and patient out-of-pocket cost trends in a commercially insured population
VJ Willey, MF Pollack, GD Lawless - Journal of Clinical Oncology, 2008 - ascopubs.org
6503 Background: Health care costs continue to rise at the same time health care purchasers
are requesting new benefit designs with greater patient cost sharing. This study examined …
are requesting new benefit designs with greater patient cost sharing. This study examined …
[HTML][HTML] Defining value in cancer care: AVBCC 2013 steering committee report
…, L Bosserman, JT Kenney Jr, GD Lawless… - American Health & …, 2013 - ncbi.nlm.nih.gov
The AVBCC Annual Meeting experiences exponential growth in attendance and participation
as oncologists, payers, employers, managed care executives, patient advocates, and drug …
as oncologists, payers, employers, managed care executives, patient advocates, and drug …
Factors associated with unintended pregnancy, contraceptive risk-taking, and interest in pharmacist-provided birth control
…, R Yacobi, GD Lawless - Journal of …, 2020 - meridian.allenpress.com
… Lawless served previously at Amgen, Inc. as Director of Healtheconomics, then Executive
Director for National Accounts Managed Care. … Lawless has no conflict of interest to report. …
Director for National Accounts Managed Care. … Lawless has no conflict of interest to report. …